Novartis Faces Shareholder Criticism Over Drug Prices At AGM | 10/23/2017 | Staff
fofo (Posted by) Level 3
ZURICH (Reuters) – Novartis’s shift into high-tech drugs won praise for giving new options to patients but criticism for prices that may run into the millions of dollars as the Swiss drugmaker faced investors at its annual general meeting on Thursday.

Swiss shareholder group Actares, which owns a small percentage of Novartis shares, said...
(Excerpt) Read more at:
Wake Up To Breaking News!
Sign In or Register to comment.

Welcome to Long Room!

Where The World Finds Its News!